# A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

> **NCT07172516** · PHASE3 · RECRUITING · sponsor: **Xenon Pharmaceuticals Inc.** · enrollment: 400 (estimated)

## Conditions studied

- Bipolar Disorder
- Bipolar Depression
- Bipolar I Disorder
- Bipolar II Disorder

## Interventions

- **DRUG:** Azetukalner
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07172516
- **Lead sponsor:** Xenon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-08
- **Primary completion:** 2028-06
- **Final completion:** 2028-08
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07172516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07172516, "A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07172516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*